Targeting PRMT9-Mediated Arginine Methylation Suppresses Cancer Stem Cell Maintenance and Elicits cGAS-Mediated Anticancer Immunity

The authors showed that targeting protein arginine N-methyltransferase 9 (PRMT9), whose activities were elevated in blasts and leukemia stem cells from patients with acute myeloid leukemia, eliminated disease via cancer-intrinsic mechanisms and cancer-extrinsic type I interferon-associated immunity.